This activity is supported by educational grants from AbbVie, Acelity, Astellas, AstraZeneca, Celgene, Eisai Inc., Genentech, Inc., Genomic Health, Inc., Lilly, Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer, Puma Biotechnology, Inc, and TESARO, Inc.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Thank you to all the attendees and faculty for making the 33rd Annual Miami Breast Cancer Conference® a success!
This year's Miami Breast Cancer Conference® is the most important and exciting because of all of the changes in treating patients with breast cancer.
Dr Borgen, 'We will tackle the mammography screening controversy at the Miami Breast Cancer Conference®'
Dr Borgen discusses the response to the Canadian Breast Screening Trial.
Hear it on Friday and use it Monday – information on screening that attendees will take home with them and use in their practice.
Dr Borgen speaks about many of the other exciting topics at the Miami Breast Cancer Conference®.
It’s an incredible time to be treating breast cancer – you need to stay up-to-date with advances to be a wise voice at your tumor boards.
Dr Borgen discusses why an oncologist that has never attended before should attend this year's Miami Breast Cancer Conference®.
Dr Borgen, 'breast cancer is a community, and nowhere does that come together better than at the Miami Breast Cancer Conference®.'
Thank you to all the attendees and faculty for making the 32nd Annual Miami Breast Cancer Conference® a success!
Photos from 33rd Annual Miami Breast Cancer Conference®
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY